Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1569912 as Adjunctive Therapy in Major Depressive Disorder
NCT04937829Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 1569912 in major depressive disorder (MDD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Decrease From Baseline in Montgomery-Åsberg Depression Rating Scale Score at 8 days and Number of Patients With Drug-related Adverse Events at 15 days. Started Jul 2021; status: completed.
02
Drugs
BI 1569912
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04937829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937829.